Entrada Therapeutics, Inc. Common Stock — Quarterly Financial Statements (NASDAQ:TRDA) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Market Capitalization 494.6484 M
Employee 183
Founded 2016
CEO N/A
Website www.entradatx.com
Headquarter Delaware, United States
FIGI BBG00MTSMC16
Industry Technology

Total revenue

Net income

Basic earnings per share (Basic EPS)

Total debt

Free cash flow

Cash & equivalents

494.65 M Market capitalization

Price to earnings ratio

-2.96

Price to sales ratio

—

Dividends per share

—

Dividend yield %

—

Notizie

Gli EPS di Entrada Therapeutics hanno battuto le aspettative per 0,04$, il fatturato appena sotto le previsioni

Entrada Therapeutics earnings beat by $0.04, revenue fell short of estimates

Arcutis Biotherapeutics, Inc. (ARQT) Surpasses Q4 Earnings and Revenue Estimates

Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates

Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline

EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains?

Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates

Techne (TECH) Beats Q2 Earnings and Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Capricor Therapeutics Stock: A High Risk/High Reward Name (NASDAQ:CAPR)

Entrada riporta progressi sui trattamenti DMD e condivide il calendario clinico

Entrada reports progress on DMD treatments, shares clinical timeline